Healthcare
Zoetis Inc.(ZTS)
Live Price
Offline$78.71
+1.88% today
1Y Change
-50.62%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $47.57B
- Revenue Growth
- +2.3%
- EPS Growth
- +10.2%
- Dividend Yield
- 1.8%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zoetis Inc. (ZTS) is a Healthcare stock with a market cap of $47.57B and listed on NYSE. The stock last traded around $78.71 and down 50.6% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +2.3%, EPS growth of +10.2%, a dividend yield of 1.8%. What stands out right now is revenue +2.3%, EPS +10.2%, free cash flow -0.7% with operating margin 38.0% and ROIC 21.5%. The dividend is present but secondary, with a yield around 1.8%. Valuation sits in the middle of the pack at P/E 18.5 and price/sales 5.0. Stock Foundry combines ZTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.3% vs +7.6% peer median
Operating Margin
Above sector median
+38.0% vs +19.4% peer median
P/E
Below sector median
18.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +2.3% and EPS at +10.2%, with operating margin around 38.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -5.1% | -13.5% | โ |
2026 Feb 12, 2026 | +5.7% | +0.8% | +2.5% | -8.0% |
2025 Nov 4, 2025 | +4.9% | -3.2% | -3.5% | -1.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZTS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZTS Max Drawdown
-53.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZTS and SPY.
Company Overview
Zoetis Inc.
New York Stock Exchange
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
- Leadership
- Kristin C. Peck
- IPO Date
- Feb 1, 2013
- Employees
- 13.8k
- Street Address
- 10 Sylvan Way
- Mailing
- Parsippany, NJ, 07054
- Region
- Parsippany, NJ, US
- Reporting Currency
- USD
- Investor Line
- 973 822 7000
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.5
- EV/EBITDA
- 13.4
- Price/Sales
- 5.0
- Price/Book
- 14.8
Growth
- Revenue
- +2.3%
- EPS
- +10.2%
- Free Cash Flow
- -0.7%
Profitability
- Gross Margin
- 70.5%
- Operating Margin
- 38.0%
- Net Margin
- 28.2%
- ROE
- 58.2%
- ROIC
- 21.5%
Balance Sheet
- Debt/Equity
- 2.85
- Current Ratio
- 3.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.